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Background: Expression of αvβ3 integrin is increased after myocardial infarction as part of the repair process.
Increased expression of αvβ3 has been shown by molecular imaging with 18F-galacto-RGD in a rat model. The
68Ga-labelled RGD compounds 68Ga-NODAGA-RGD and 68Ga-TRAP(RGD)3 have high specificity and affinity, and may
therefore serve as alternatives of 18F-galacto-RGD for integrin imaging.
Methods: Left coronary artery ligation was performed in rats. After 1 week, rats were imaged with [13N]NH3,
followed by 18F-galacto-RGD, 68Ga-NODAGA-RGD or 68Ga-TRAP(RGD)3 using a dedicated animal PET/CT device. Rats
were killed, and the activity in tissues was measured by gamma counting. The heart was sectioned for
autoradiography and histology. Immunohistochemistry was performed on consecutive sections using CD31 for the
endothelial cells and CD61 for β3 expression (as part of the αvβ3 receptor).
Results: In vivo imaging showed focal RGD uptake in the hypoperfused area of infarcted myocardium as defined with
[13N]NH3 scan. In autoradiography images, augmented uptake of all RGD tracers was observed within the infarct area
as verified by the HE staining. The tracer uptake ratios (infarct vs. remote) were 4.7 ± 0.8 for 18F-galacto-RGD, 5.2 ± 0.8
for 68Ga-NODAGA-RGD, and 4.1 ± 0.7 for 68Ga-TRAP(RGD)3. The
68Ga-NODAGA-RGD ratio was higher compared to
68Ga-TRAP(RGD)3 (p = 0.04), but neither of the
68Ga tracers differed from 18F-galacto-RGD (p > 0.05). The area of
augmented 68Ga-RGD uptake was associated with β3 integrin expression (CD61).
Conclusion: 68Ga-NODAGA-RGD and 68Ga-TRAP(RGD)3 uptake was equally increased in the infarct area at 1 week post
infarction as 18F-galacto-RGD. These results show the potential of 68Ga-labelled RGD peptides to monitor integrin
expression as a part of myocardial repair and angiogenesis after ischaemic injury in vivo.
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Healing of myocardial infarct (MI) is a dynamic process,
with stages of initial inflammation, angiogenesis, fibro-
blast proliferation and collagen deposition followed by
scar formation in the maturation and remodelling phase
[1]. Inadequately healed MI results in infarct area expan-
sion and dilatation of the heart by left ventricle (LV) re-
modelling, ultimately developing into chronic heart
failure [2,3]. Angiogenesis is a central part of infarct* Correspondence: iina.laitinen@gmail.com
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in any medium, provided the original work is phealing and is characterised by activation of angiogenic
factors and expression of signalling molecules such as
integrins. One particularly interesting member of this
family is the integrin αvβ3. It is a cell-membrane glyco-
protein receptor that is quiescent under normal condi-
tions, but its expression and activation is up-regulated
on the endothelial cells when angiogenesis takes place,
such as in the infarct area after ischaemic myocardial in-
jury [4]. Radiolabelled antagonists containing the αvβ3-
specific cyclic RGD peptide can be used for molecular
imaging of αvβ3 integrin expression after MI [5-7]. Up-
take is the highest at 1 week after infarct corresponding
to the peak time of neovessel formation [5]. Our recentan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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(18F-galacto-RGD) in the infarct area at 1 week after MI
predicts improved healing in the form of less LV remod-
elling seen 12 weeks after the injury [8]. Taken together,
imaging of αvβ3 integrin expression is an attractive tool
to assay the post-MI angiogenesis and may be potentially
used to predict outcome of infarct healing.
The production of 18F-galacto-RGD requires an
on-site cyclotron and a multi-step synthesis, which is chal-
lenging to transfer to good manufacturing practice (GMP)
conditions. Therefore, alternative RGD compounds have
been sought after, such as a one-step-labelled positron-
emission tomography (PET) tracer,18F-AIF-NOTA-PRGD2,
which was also found to reflect ischaemia-induced angio-
genesis in a rat model [7].68Ga-NODAGA-cyclo(RGDyK)
and 68Ga-TRAP(cyclo(RGDfK))3 have been evaluated for
αvβ3 imaging in tumour models, showing high target-to
-background ratios [9-12]. 68Ga tracers have the advantage
of easy and fast production with a generator-produced
radionuclide. 68Ga-NODAGA-RGD and particularly
68Ga-TRAP(RGD)3 can be produced with high specific
activity (approximately 200 to 600 GBq/μmol for
68Ga-NODAGA-RGD and over 5 TBq/μmol for 68Ga-
TRAP(RGD)3 [9,11]), which is essential when using
68Ga-labelled peptides, especially in case of small ani-
mal studies.
In this study we sought to evaluate 68Ga-NODAGA-
RGD and 68Ga-TRAP(RGD)3 for targeting αvβ3 integrin
in comparison to 18F-galacto-RGD using a well-defined
rat model of myocardial infarct [6,8]. We investigated
the uptake of all three tracers using in vivo and ex vivo




Permanent ligation of the left anterior descending cor-
onary artery was performed, as previously described [8]
in 34 healthy male Lewis rats (Charles Rivers Laborator-
ies, Sulzfeld, Germany) aged 8 to 10 weeks to induce
MI. Briefly, the rats were anaesthetised with intramuscu-
lar administration of midazolam 5 mg/kg (Dormicum®,
Roche; Grenzach-Wyhlen, Germany), medetomidin 0.5
mg/kg (Dormitor®, Pfizer, Karlsruhe, Germany) and fen-
tanyl 0.05 mg/kg (Ratiopharm, Ulm, Germany) and
connected to a rodent ventilator. The heart was exposed
through a left lateral thoracotomy of the fourth intercos-
tal space, and the left anterior descending (LAD) artery
was ligated near to its origin (2 to 3 mm from the tip of
the left atrium). Two rats underwent sham operation,
which consisted of the same procedures except that the
LAD artery suture was not tightened. The rats were
treated with 0.05 mg/kg buprenorphin (Temgesic®, Essex,
Germany) and 4 mg/kg carprofen (Rimadyl, Pfizer,Germany) for 72 h post surgery. The study protocols were
approved by the regional governmental commission for
animal protection (Regierung von Oberbayern, Munich,
Germany).
Tracer preparation
The radiosynthesis and quality control of 18F-galacto-
RGD (18F-galacto-cyclo(RGDfK)), 68Ga-NODAGA-RGD
(68Ga-NODAGA-cyclo(RGDyK)) and 68Ga-TRAP(RGD)3
(68Ga-TRAP(cyclo(RGDfK))3) were performed as described
previously [9-12].
Uptake of RGD in tissues
Rats were anesthetised using 1.5% isoflurane and were
injected via tail vein catheter with 18F-galacto-RGD (37
MBq, n = 9), 68Ga-NODAGA-RGD (69 MBq, n = 10) or
of 68Ga-TRAP(RGD)3 (54 MBq, n = 12). Rats were
kept under anaesthesia in a warmed bed until euthanized
after 90 min using intravenous injection of 150 mg/kg
of pentobarbiturate (Narcoren®, Merial, Rohrdorf,
Germany). The heart was excised and cut transaxially at
the location of the infarct. The apical part, containing
both infarct and non-affected remote myocardium, was
processed for sectioning for autoradiography as de-
scribed below.
Tissue samples (remote myocardium, apical part of
myocardium, femoral muscle, operation wound and the
connective tissue contralateral to the wound, spleen,
liver, kidney, urine and blood) were dissected, and the
weights of the tissue, urine, blood and serum samples
were measured and their activity was detected using a
gamma counter (1480 Wizard, PerkinElmer Wallac,
Turku, Finland).
In order to determine the blood clearance, blood
samples were drawn from a subset of animals (68Ga-
NODAGA-RGD, n = 3; 68Ga-TRAP(RGD)3, n = 3) at 1,
5 and every 10 min after injection using a second tail
vein catheter.
The specificity of the RGD binding was studied on
three rats with pre-injection of a blocking dose of
cilengitide (18 mg/kg = 30.6 μmol/kg) 10 min prior to
the tracer injection [12-15].
Autoradiography
The excised hearts were frozen and embedded in Tissue
TekW mounting media (Sakura Finetek Europe B.V.,
Alphen aan den Rijn, the Netherlands). Serial LV short-
axis cryosections of 20-μm thickness were obtained.
Similar sections of muscle and spleen samples of the
same rat were processed and used as negative and posi-
tive controls. After quick air drying, the sections were
exposed to an imaging plate (Kodak Storage Phosphor
screen GP, Eastman Kodak Company, Rochester, NY,
USA). After an overnight exposure, the imaging plates
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Dürr Medical, Raytest Isotopenmeßgeräte GmbH,
Germany; internal resolution of 25 μm), and the images
were analysed for background-corrected count densities
(PSL/mm2) with an image analysis programme (AIDA
Image Analyser, Raytest Isotopenmeßgeräte, Germany).
Later, the same sections were stained with hematoxylin-
eosin (HE) for delineation of the affected area in the
myocardium.
After careful co-registration of the autoradiographs
and HE histological images, regional tracer uptake was
analysed in the following two regions: (1) the infarcted
myocardium containing the border zone as assessed
after HE staining and (2) the remote, non-affected myo-
cardium. The analysis was based on 12 to 15 sections
from each heart. The results were expressed as a ratio of
the mean value of activity in the infarct area divided by
the mean value of activity in the remote area.
PET imaging
A subset of animals (n = 7) was imaged using a small-
animal PET/CT scanner (Inveon, Siemens Medical Solu-
tions, Knoxville, TN, USA). The rats were anaesthetised
using 1.5% isoflurane. Breathing was monitored and
temperature was maintained using a heating pad
throughout the imaging procedures. The rats were
injected with 37 MBq of [13N]NH3 via tail a vein cath-
eter, and perfusion images were acquired for 15 min
starting at the time of injection. A CT scan was
performed for anatomical localisation. The animals were
left anaesthetised in the scanner, and 60 min later, the
animals were injected with either 68Ga-NODAGA-RGD
(72 MBq, n = 4) or 68Ga-TRAP(RGD)3 (63 MBq, n = 3)
via the tail vein. Dynamic PET data were acquired from
the start of the injection for 90 min in a list mode. The
rats were euthanized immediately after, and the tissues
were processed as described above.
PET data were reconstructed using a 3D-filtered back-
projection algorithm. The resulting matrix was 128 ×
128 pixels with 159 transverse slices (voxel size of 0.78 ×
0.78 × 0.80 mm3). Data were normalised and corrected
for randoms, dead time and decay. No corrections were
made for attenuation or scatter.
The CT acquisition consisted of 120 projections ac-
quired with exposure time of 200 ms, X-ray voltage of
80 kVp and anode current of 500 μA for 220° rotation.
CT images were reconstructed using a modified
Feldkamp algorithm. The resulting matrix was 256 ×
256 pixels with 631 transverse slices (reconstructed
voxel size 0.21 × 0.21 × 0.21 mm3).
The 68Ga- and 13N-PET images were fused, and the
uptake was visualised using the Inveon Research Work-
place (Siemens, Knoxville, TN, USA). PET and CT im-
ages were co-registered for anatomical reference.Regions of interest (ROI) were manually drawn around
the focal 68Ga-RGD uptake area in the myocardium on a
transverse image, corresponding to 13N signal loss. This
was repeated on four consecutive transverse images to
cover the infarct area. The mean radioactivity concentra-
tion within the ROI was expressed as the percentage of
injected dose per cubic centimetre (% ID/cc).
Immunohistochemistry
Five-micron LV short-axis sections were processed adja-
cent to the plane of sections for autoradiography. To
visualise the endothelial cells, macrophages and β3
integrin expression in the myocardium, sections were
stained with the following antibodies: CD31 (BD
Pharmingen, Franklin Lakes, NJ, USA), F4/80 (Abcam,
Cambridge, UK) and CD61 (BD Pharmingen, Franklin
Lakes, NJ, USA). The sections were analysed for the ex-
tent of positive staining in remote, borderzone and in-
farct by light microscopy at ×400 magnification. After
averaging the positive counts of ten fields, the vascular
density and macrophage and β3 integrin expression were
calculated per area (high-power field). For correlation
with RGD uptake in the autoradiograms, the borderzone
and infarct area results were pooled.
Statistical analysis
All data are expressed as mean ± standard deviation.
The p values of <0.05 were considered as statistically sig-
nificant. For comparison between two groups, Student's
t test for unpaired data was used. ANOVA with Tukey-
Kramer adjustment was used for comparisons of three
different groups. For the correlation between two con-
tinuous variables, linear regression with Pearson's or
Spearman's (for non-parametric) rank test was used.
Results
Animal model
Ligation of the LAD resulted in a myocardial infarction,
which covered 15% to 25% of myocardial axial plain, as
measured from autoradiography sections. Out of 34 op-
erated rats, two died within 24 h after surgery and one
during the imaging day, and one had 100% infarct in
cross section and was therefore excluded. Average body
weights were 310 ± 54 g and did not differ between the
groups.
Immunohistochemical staining showed increased
density of vessels, macrophages and β3 integrin in the
border zone (Figures 1 and 2). The sprouting vessels in
the myocardial infarct showed upregulation and expres-
sion of β3 integrin, whereas only a faint expression in
the muscle cells in the remote myocardium was ob-
served (Figure 2). There were no differences between
groups on the vascular density (72 ± 5 vs. 75 ± 5), mac-
rophages (15 ± 6 vs. 17 ± 5) or CD61 positive cells (63 ±
Figure 1 Vascular density (CD31) and β3 integrin expression
(CD61) in remote, borderzone and infarct areas. Average ± SD of
positive counts of 10 high power field (×400 magnification).
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TRAP(RGD)3 groups, respectively). The size of the focal
uptake area in the autoradiogram sections was comparable
between the three groups (8.2 ± 5.1; 7.3 ± 3.2 and 7.4 ±
4.5 mm2 for 18F-galacto-RGD, 68Ga-NODAGA-RGD and
68Ga-TRAP(RGD)3, respectively).
PET-CT in vivo imaging
Augmented uptake of both 68Ga-RGD tracers co-
localised to the [13N]NH3 area of hypoperfusion (low
signal) in the myocardium as seen in the transversal axis
images (Figure 3). A substantial uptake was seen also in
the operation scar, which could be verified with co-Figure 2 Representative myocardial sections. HE, CD31
(endothelial cells), CD61 (β3 integrin) and F4/80 (macrophages)
staining in infarct, border zone and remote areas. Original image
×400 magnification.registered PET and CT images. The image-derived aver-
age uptakes in the myocardium were 0.17 ± 0.03 and
0.25 ± 0.02% ID/cc for infarct areas at 82.5 min after
injection for 68Ga-NODAGA-RGD (n = 4) and 68Ga-
TRAP(RGD)3 (n = 3), respectively. Compared to the up-
take in the remote myocardium, the infarct-to-remote
ratios were 2.1 for 68Ga-NODAGA-RGD and 1.9 for
68Ga-TRAP(RGD)3.Ex vivo biodistribution
The accumulated activity of 68Ga in tissues as measured
with gamma counting is presented in Table 1. The
highest 68Ga activities were seen in the urine and kidney,
indicating renal excretion as previously reported in mice
[10-12]. The uptake values were comparable, independ-
ent of the weight of the animal or injected dose, with ex-
ception of the healthy connective tissue, muscle and
remote myocardium where 68Ga-TRAP(RGD)3 (n = 10) up-
take was found to be higher compared to 68Ga-NODAGA-
RGD (n = 9). The blood time activity curves showed similar
kinetics of all three tracers with rapid clearance from the
circulation (Figure 4 and in [6]).
The apical part of the myocardium, containing both in-
farcted and remote myocardial tissue, was measured be-
fore processing into sections. The uptake was higher in
the apical part as compared to the remote myocardium
tissue sample (apical-to-remote ratio 2.4 (p > 0.01) for
68Ga-NODAGA-RGD and 2.1 (p > 0.01) for 68Ga-TRAP
(RGD)3).Ex vivo autoradiography of RGD tracer uptake in the
myocardium
In autoradiography images, an augmented uptake of all
three tracers was observed within the infarct area as
verified by HE staining (Figure 5). The infarct vs. remote
PSL/mm2 uptake ratios were 4.7 ± 0.8, 5.2 ± 0.8 and 4.1
± 0.7 for 18F-galacto-RGD (n = 8), 68Ga-NODAGA-RGD
(n = 7) and 68Ga-TRAP(RGD)3 (n = 7), respectively
(Figure 6). The 68Ga-NODAGA-RGD infarct-to-remote
ratio was higher as compared to 68Ga-TRAP(RGD)3
(p = 0.04), but neither of the 68Ga tracers differed from
18F-galacto-RGD (p > 0.05).
The tracer distribution in the myocardium of the sham-
operated rats was uniform and comparable to the remote
area of the operated rats (Figure 5). Pre-injection of
high-dose cilengitide [12-15] reduced the uptake in the
myocardium and also in the spleen, demonstrating specific
binding (Figure 5). Infarct-to-remote ratio was 1.7 for both
tracers when blocked with cilengitide (n = 3).
The RGD uptake in the infarct and borderzone area of
the myocardium, normalised to the remote area, corre-
lated with β3 integrin expression (R = 0.91) (Figure 7).
Figure 3 In vivo PET/CT images of rat MI. Representative transaxial sections show hypoperfused myocardium area (13N) and corresponding
RGD uptake (68Ga, % ID/g). The focal uptake is seen in infarct (yellow arrowheads) and the operation scar (white arrows), as verified by CT scan.
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Studies in the rat model of myocardial infarct have
shown that monitoring the expression of αvβ3 integrin
by molecular imaging provides valuable prognostic infor-
mation about myocardial repair after infarct [5-8].
First studies with animal models and humans using
18F-galacto-RGD have been promising, but further stud-
ies using this tracer are limited due to the difficulties of
producing 18F-galacto-RGD in compliance with the
GMP. Therefore, we sought to study new 68Ga-labelled
RGD tracers for the use for MI imaging. Using in vivo
imaging and ex vivo autoradiography analysis, we show
that 68Ga-NODAGA-RGD and 68Ga-TRAP(RGD)3 accu-
mulate in the myocardial infarct area in a similar man-
ner as 18F-galacto-RGD. Autoradiography analysis
revealed 4.1 to 5.2 times higher uptake in the infarct
area as compared to the remote myocardium. Both




Blood 0.058 ± 0.02
Serum 0.094 ± 0.05
Remote myocardium 0.071 ± 0.03
Apical myocardium 0.156 ± 0.06
Muscle 0.035 ± 0.01
Connective tissue 0.110 ± 0.05
Wound 0.270 ± 0.24
Spleen 0.246 ± 0.16
Liver 0.230 ± 0.17
Kidney 1.102 ± 0.70
Urine 20.24 ± 6.40
Ns, not significant; p.i., post-injection. Results presented as percentage of injected d
and remote areas, as can be seen in processed transaxial sections for autoradiograpthis finding, although attenuation, partial volume and
signal spillage diminished the acquired infarct-to-remote
ratios obtained using these methods. In comparison to
18F-galacto-RGD, neither of the 68Ga-labelled tracers
was superior, but when compared between each other,
68Ga-NODAGA-RGD had slightly higher infarct-to-remote
myocardium ratio in the autoradiograms. This was not af-
fected by the infarct size, vascular density or macrophage
count. Moreover, we found that the RGD uptake correlated
with β3 integrin expression in the myocardium.
Integrins have been shown to be essential in
maintaining the homeostasis of the myocardium after
pathologic stressors, such as myocardial infarct injury
[16]. Adverse healing of infarct leads to maladaptive
hypertrophic growth of the left ventricle and, therefore,
biomarkers for early detection are sought after. In
addition to the role in the formation of neovessels dur-
ing the granulation phase of infarct healing, the αvβ3(RGD)3 in tissues 90 min p.i
68Ga-TRAP(RGD)3
Mean ± SD
n = 10 p Value
0.101 ± 0.07 ns
0.166 ± 0.12 ns
0.154 ± 0.09 0.02
0.353 ± 0.10 -
0.066 ± 0.03 0.028
0.190 ± 0.08 0.031
0.256 ± 0.12 ns
0.415 ± 0.30 ns
0.524 ± 0.61 ns
1.447 ± 0.51 ns
35.10 ± 22.37 ns
ose per gram of tissue (% ID/g). The apical myocardium contains both infarct
hy.


















Figure 4 Blood clearance as measured by gamma counting.
Closed symbols 68Ga-NODAGA-RGD, open symbols 68Ga-TRAP(RGD)3.
Figure 5 Autoradiograms of myocardial cross sections. 68Ga-NODAGA-
operated controls and with a pre-injection of blocking dose of cilengitide.
(arrow, contour), digitised autoradiogram of the same section where focal
of the spleen (positive control) and muscle (negative control), with the sam
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cesses. β3 integrin together with β1 integrin play a role
in hypertrophic growth via the activation of survival
mechanisms by attenuating myocyte apoptosis [16-19].
Therefore, molecular imaging of integrin expression may
offer an attractive way to improve risk assessment of
post-MI patient and may serve as a biomarker for
targeted therapy.
Cyclic RGDfK pentapeptides have been extensively
studied for αvβ3 integrin imaging [20,21]. Cyclic RGDfK
and RGDyK compounds have a high affinity in the
nanomolar range to αvβ3 and αvβ5 and have selectivity
over other integrin subtypes [22,23]. Several RGD com-
pounds for PET and SPECT have been introduced for
integrin imaging in malignant tumours and angiogenesis
[24]. The potential of αvβ3 targeting RGD peptides for
imaging of myocardial infarct healing has also beenRGD and 68Ga-TRAP(RGD)3 uptake at 1 week after MI, in sham-
From left to right: HE-stained 20-μm section, delineated infarct area


























   
   
Figure 6 RGD uptake ratio in MI autoradiograms. Mean infarct
to remote ratio of PSL/mm2 and SD of three tracers.
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99mTc-RAFT-RGD [25] and 18F-AlF-NOTA-PRGD2 [7].
68Ga-NODAGA-RGD is a cyclic RGD pentapeptide
conjugated with a NODAGA chelator without affecting
the binding affinity. 68Ga-TRAP(RGD)3 [12] is a trimer
based on a TRAP chelator for gallium(III) binding
[11,26,27]. The specificity of 68Ga-NODAGA-RGD and
68Ga-TRAP(RGD)3 has been demonstrated in cell culture
and mouse models [10-12], as well as for 18F-galacto-RGD
in the same animal model as used in this study [6,8]. We























Figure 7 Correlation of β3 integrin expression (CD61) and RGD
uptake. Pooled results from autoradiography ratios of 68Ga-
NODAGA-RGD (closed symbols) and 68Ga-TRAP(RGD)3 (open
symbols) uptake (R = 0.91).cilengitide, a cyclic RGD peptide with high affinity for αvβ3
and αvβ5 integrins [14,15], diminished the
68Ga-NODAGA-
RGD and 68Ga-TRAP(RGD)3 signal in the infarcted area of
the myocardium and in the other measured tissues such as
spleen and muscle, showing that the signal in these tissues
is specific to integrin expression.
The affinity of trimeric 68Ga-TRAP(RGD)3 to αvβ3 in-
tegrin is more than seven times higher than that of the
monomers 68Ga-NODAGA-RGD and 18F-galacto-RGD
(IC50 of 44 nM vs. 336 nM and 319 nM, respectively, de-
termined in a competitive displacement assay on M21
human melanoma cells [9,10]). Multimerisation of the
RGD molecule has been shown to increase affinity
[20,28,29], but not necessarily the tumour-to-back-
ground ratio. This can be due to the specific (blockable)
uptake of the ‘background’ tissue, which may express
small amounts of the integrin. Another explanation can
be the relatively low local concentration of the integrins
in the target area and hence lack of bivalency binding of
a multimeric molecule [10,30,31]. We also found a similar
effect: the infarct-to-remote ratio in myocardium was not
increased in the case of 68Ga-TRAP(RGD)3. In this case,
the increased affinity of 68Ga-TRAP(RGD)3 to the small
amount of integrin present in remote myocardium [4] re-
sults in a higher overall uptake, as was seen in vivo and
ex vivo when compared to 68Ga-NODAGA-RGD (Table 1).
The selective and specific binding of cyclic RGD mole-
cules to αvβ3 and αvβ5 integrins has been established
with in vitro methods as well as in vivo experiments
(reviewed in [20,32]). The αvβ3 integrin expression is
upregulated in several cancer cell lines [33] and in
sprouting and activated vessels during wound healing of
the skin, muscle and myocardium [4,34,35]. In suppor-
ting the earlier data of integrin location [4], the recent
study by Gao and co-workers used dual immunofluores-
cence staining to demonstrate dominant co-localisation
of CD61 (β3) signal with CD31-positive endothelial cells
at 1 week after experimental ischaemia-reperfusion-
induced infarct [7]. We also show that RGD signal cor-
relates with the number of CD61-positive cells in
permanent ligation-induced MI. Previously, we have
shown that 18F-galacto-RGD uptake does correlate to
the vascular density in the infarct area, but does not
correlate to the amount of macrophages at 1 week after
injury [8]. At 3 days after myocardial ischaemia reperfu-
sion injury, Gao and colleagues did not find a strong co-
localisation of CD61 and CD31 [7], which could indicate
that the other cells might be responsible for RGD signal
at this earlier time point. Myofibroblasts also express
αvβ3 integrins and can be targeted with a pro-
collagen-targeting Cy5.5-RGD imaging peptide [36].
In addition to neovessels and myofibroblasts, macro-
phages have also been shown to express αvβ3 integrin
[37]. However, the relative amounts of integrin in
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MI. The temporal changes of the expression of αvβ3
and other integrins and, therefore, the cellular
localization of the signal of labelled cRGD compounds
in the case of myocardial infarct still warrant further
studies.
Taken together, we as well as several other groups have
established the use of integrin imaging in monitoring of
myocardial infarct healing and the feasibility of cyclic
RGD compounds for that purpose. The current require-
ments for the production of radiopharmaceuticals in
GMP compliance have made the clinical use of 18F-galacto-
RGD difficult. There is an increasing number of different
RGD imaging compounds available, but which candidate
should be selected further for clinical use is an open ques-
tion. Although high specificity and selectivity to integrins
and high affinity are necessary qualities, the selection for a
clinically usable tracer needs to take into account the
practical issues such as the ease and safety of the produc-
tion. 68Ga tracers appeal to sites with no cyclotron close
by, but for instance, the FASTlab production cassette for
18F-fluciclatide is also already available [38], which will fa-
cilitate the clinical use of this RGD-containing tracer using
F-18 and a distribution network. Ultimately, the resulting
imaging quality is a factor that cannot be compromised.
Conclusions
Prominent in vivo and ex vivo signal of 68Ga-NODAGA-
RGD and 68Ga-TRAP(RGD)3 was found in the myocar-
dium of rats at 1 week post infarct, localising to the area
of hypoperfusion and β3 integrin expression. Both
68Ga-
NODAGA-RGD and 68Ga-TRAP(RGD)3 showed similar
binding behaviour in the myocardium after infarct as
18F-galacto-RGD. These results show the potential of
68Ga-labelled cyclic RGD peptides to monitor angiogen-
esis after myocardial injury in vivo.
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